Biomedical Advanced Research and Development Authority (BARDA)

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Eradivir is a biotech company established in 2020 and based in West Lafayette, Indiana. The company focuses on developing a novel bispecific immunotherapy platform aimed at combating the virus responsible for COVID-19. Eradivir's approach involves creating non-immunological targeting agents that possess high specificity and avidity for a unique domain of the spike protein found on various coronaviruses. This innovation enables the effective elimination of both free viruses and virus-infected cells, even during advanced stages of infection, thereby empowering patients' immune systems to address viral challenges more efficiently.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

Care Access Research provides clinical research and clinical trial services. Care Access Research goal is to engage every healthcare professional in clinical research and to make clinical trials a care option for every patient.

CastleVax operates as a clinical-stage vaccine research company. CastleVax is reimagining how to provide safe and effective vaccines for all humans, everywhere.

Walgreens is the largest drugstore chain in the United States, operating 7,689 locations across all 50 states, the District of Columbia, and Puerto Rico. The company serves nearly 6 million customers daily, offering convenient access to a wide range of consumer goods, pharmacy services, and health and wellness solutions. Walgreens provides various pharmacy services, including retail, specialty, infusion, medical facility, and mail services, alongside respiratory care. These services aim to enhance health outcomes while reducing costs for various stakeholders, including employers and managed care organizations. A subsidiary of Walgreens, Take Care Health Systems, manages over 700 worksite health centers and in-store clinics, further expanding the company's reach in providing accessible healthcare solutions.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Battelle is the largest independent research and development organization globally, based in Columbus, Ohio. Established in 1929, it operates as a nonprofit private foundation focused on advancing scientific discovery and innovation. Battelle brings together experts in various fields to foster collaboration between people, science, and technology, aiming to accelerate advancements that benefit society. The organization is governed by a board of directors, ensuring that its resources are directed towards impactful research and development initiatives.

Draper is a non-profit laboratory established in 1973, located in Cambridge, Massachusetts, that focuses on applied research, engineering development, education, and technology transfer. The laboratory provides engineering services to governments, industries, and academic institutions, acting as both a prime contractor and subcontractor, while also participating in collaborative consortia. Draper offers impartial assessments of technologies or systems proposed by other organizations. Its areas of specialization include precision instrumentation, fault-tolerant and autonomous systems, image and data analytics, human systems technology, materials engineering and microfabrication, as well as biomedical solutions.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Rivanna Medical, LLC is a medical technology company based in Charlottesville, Virginia, founded in 2010. The company focuses on developing and commercializing innovative ultrasound-based systems aimed at enhancing the application of spinal and epidural anesthesia through advanced 3D navigation of the lumbar spine. Its flagship product, Accuro, not only facilitates precise anesthesia delivery but also supports various diagnostic imaging needs, including musculoskeletal and abdominal anatomies. Rivanna Medical is committed to improving patient outcomes and lowering healthcare costs while minimizing patient exposure to radiation commonly associated with X-ray-based imaging techniques.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

The Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are disproportionately affected by infectious diseases. The organization focuses on developing innovative vaccines aimed at preventing a wide range of illnesses, ensuring that these vital health resources are available to communities worldwide. By emphasizing the importance of immunization coverage, the Sabin Vaccine Institute seeks to improve overall healthcare outcomes and contribute to the prevention of diseases on a global scale.

OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices used for detecting critical medical conditions. The company operates primarily in two segments, focusing on a diverse range of products that include rapid tests for HIV, HCV, and Ebola, as well as drug testing and alcohol testing solutions. Notable offerings include the OraQuick Rapid HIV test, the Intercept Oral Fluid Drug Testing System, and the Q.E.D. Saliva Alcohol Test. Additionally, OraSure provides genomic products through its subsidiary, DNA Genotek, which specializes in oral fluid sample collection for molecular diagnostics. The company's products cater to clinical laboratories, hospitals, community organizations, and government agencies, and are available in pharmacies across multiple continents. Founded in 2000 and headquartered in Bethlehem, Pennsylvania, OraSure Technologies is committed to advancing diagnostic solutions and improving public health outcomes.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

The Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are disproportionately affected by infectious diseases. The organization focuses on developing innovative vaccines aimed at preventing a wide range of illnesses, ensuring that these vital health resources are available to communities worldwide. By emphasizing the importance of immunization coverage, the Sabin Vaccine Institute seeks to improve overall healthcare outcomes and contribute to the prevention of diseases on a global scale.

Arcturus Therapeutics is an RNA medicines company based in San Diego, California, founded in 2013. It specializes in the discovery and development of novel RNA therapeutics aimed at treating rare diseases, particularly in the areas of liver and respiratory care. The company leverages its proprietary Self-Transcribing and Replicating RNA (STARR) technology and Unlocked Nucleic Acid (UNA) chemistry to create RNA drug substances and nanoparticle-formulated products. Arcturus's pipeline includes several preclinical and clinical programs, such as LUNAR-OTC for ornithine transcarbamylase deficiency, LUNAR-CF for cystic fibrosis, and LUNAR-COV19, a vaccine candidate targeting the Coronavirus outbreak. The company holds a robust patent portfolio, encompassing 182 patents and applications globally, enabling it to target any gene in the human genome. Furthermore, Arcturus has established collaborations with various pharmaceutical partners to advance its therapeutic candidates across multiple disease indications.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

EverGlade Consulting is a national consulting firm that offers management consulting solutions. The firm provides government funding, product development, litigation support, CHIPS funding applications, and DOE Loan Program application support solutions. It helps clients navigate the federal landscape. Its company incorporates market-based analytics based on industry, allowing us to focus more on organizational operations.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

The Stevanato Group S.p.A. is a global manufacturer specializing in packaging containers made from glass tubing, specifically for the pharmaceutical industry. The company focuses on providing high-quality solutions that meet the stringent requirements of pharmaceutical packaging. With a commitment to innovation and quality, Stevanato Group serves a worldwide market, catering to the needs of various stakeholders in the pharmaceutical sector.

Opiant Pharmaceuticals is a specialty pharmaceutical company based in Santa Monica, California, focused on developing treatments for addictions and drug overdoses. The company is known for its NARCAN nasal spray, which is used to reverse opioid overdoses. Opiant's product pipeline includes therapies for opioid overdose, alcohol use disorder, acute cannabinoid overdose, and other substance use disorders. Founded in 2005 and formerly known as Lightlake Therapeutics, Opiant employs a team of addiction experts and utilizes intranasal and injectable delivery technologies for its treatments. The company primarily generates revenue through royalties and licensing agreements.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Cepheid is a molecular diagnostics company specializing in developing, manufacturing, and distributing accurate yet user-friendly molecular systems and tests. Its automated solutions streamline complex genetic testing procedures, enabling institutions of all sizes to perform sophisticated analyses for infectious diseases and cancer. Cepheid's focus lies in applications where timely, precise results are crucial, such as managing infectious diseases and cancer.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

QuidelOrtho is a diagnostics company based in San Diego, California, established in 1937. It specializes in the development, manufacturing, and marketing of point-of-care diagnostic solutions for infectious diseases, reproductive health, and women's health. The company offers a range of diagnostic tests under various brand names, including QuickVue and MicroVue, addressing conditions such as influenza, strep throat, pregnancy, and bacterial vaginosis. Additionally, QuidelOrtho provides immunoassay tests for detecting blood in stool samples and serological tests for Helicobacter pylori. Its products are utilized in physician offices, hospitals, clinical laboratories, and wellness screening centers, distributed through a network of national and regional distributors as well as a direct sales force primarily in the United States and internationally in regions like Japan, Europe, and the Middle East. The company also collaborates with BioHelix Corporation to develop in vitro molecular diagnostic tests using isothermal amplification technology. QuidelOrtho generates a significant portion of its revenue from the North American market while maintaining a presence in EMEA, China, and other regions.

Corning Incorporated, headquartered in Corning, New York, is a global leader in manufacturing glass, ceramics, and related materials. Established in 1851, the company operates across several segments, including Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment produces glass substrates for organic light-emitting diodes and liquid crystal displays utilized in televisions and computers. In Optical Communications, Corning provides optical fibers, cables, and various hardware solutions for telecommunications networks. The Environmental Technologies segment focuses on emissions control products for the automotive sector, while Specialty Materials includes advanced formulations for glass and ceramics. The Life Sciences segment offers laboratory products, including consumables and pharmaceutical glass packaging. Corning also develops Gorilla Glass for mobile devices and collaborates with companies like Intel Corporation to enhance technology solutions. Through its diverse product offerings, Corning aims to meet evolving market demands and support innovation in dynamic industries.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

RxSight, Inc. is a medical technology company focused on enhancing vision outcomes for patients after cataract surgery. Based in Aliso Viejo, California, the company develops the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL) and the Light Delivery Device (LDD). This innovative system allows surgeons to customize and optimize patients' visual acuity post-surgery, making it the first commercially available intraocular lens technology that enables such personalization. The LAL incorporates ActivShield™ technology, a unique UV protection layer that further enhances its functionality. Founded in 1997 and originally known as Calhoun Vision, RxSight changed its name in 2017 to reflect its commitment to advancing ophthalmic care through precision lens technology.

Vela Diagnostics Pte. Ltd. specializes in developing advanced tools for sample processing, including sample lysis, nucleic acid extraction, and polymerase chain reaction (PCR). The company has created a platform that enhances clinical, technical, and economic outcomes in diagnostics. Vela Diagnostics provides comprehensive profiling and analytics capabilities, which are essential for medical decision-making and the detection of various bacteria, viruses, and gene mutations. By equipping diagnostic laboratories with innovative solutions, Vela Diagnostics enables them to deliver accurate and relevant research and diagnostic results, ultimately supporting improved patient care.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Emergent BioSolutions is a global life sciences company based in Gaithersburg, Maryland, founded in 1998. The organization focuses on developing, manufacturing, and delivering medical countermeasures aimed at addressing biological and chemical threats, as well as emerging infectious diseases. It operates through three segments: Commercial, Products, and Services. The Commercial segment is the primary source of revenue, featuring products such as NARCAN, which is designed to counteract opioid overdoses. By providing essential public health products to government agencies and healthcare providers, Emergent BioSolutions plays a crucial role in enhancing safety and health on a global scale.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

GenMark Diagnostics is a molecular diagnostics company specializing in the development and commercialization of innovative testing systems that utilize proprietary eSensor electrochemical detection technology. The company offers the ePlex instrument, which combines automated nucleic acid extraction and amplification, allowing for rapid testing of respiratory pathogens by placing patient samples directly into disposable test cartridges. Additionally, GenMark provides the XT-8 System, which has received FDA clearance and can analyze up to 24 test cartridges simultaneously, producing results within 30 minutes of receiving a sample. This system supports a variety of diagnostic tests, including those for respiratory viruses, cystic fibrosis, and hepatitis C genotyping. GenMark Diagnostics sells its products through direct sales and specialized service organizations in the United States and Europe, and is headquartered in Carlsbad, California. The company is also working on the next-generation AD-8 System, which aims to further streamline the testing process by integrating DNA amplification with its sensor detection technology.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

BioFactura, Inc. is a biotechnology company based in Frederick, Maryland, focused on developing and manufacturing high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. The company utilizes its patented StableFast Biomanufacturing Platform, which enables the rapid generation of stable NS0 cell lines for biopharmaceutical manufacturing. This platform features a chemically-defined, serum- and cholesterol-free production medium, pre-adapted parental cells, and modular expression vectors, allowing for the development of clonal production cell lines that can yield over one gram of product in less than eight weeks. Additionally, BioFactura offers a range of services, including expression system development, purification process development, microbial and cell culture process development, custom analytical development, and scale-up manufacturing services. The company also provides research, consulting, and contract services, thereby supporting the commercialization of innovative medical products with enhanced speed and quality. Established in 2001, BioFactura aims to meet the growing demands in the biopharmaceutical sector.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative treatments for liver disease, obesity, and vaccines. The company’s pipeline includes HepTcell, an immunotherapeutic candidate for chronic hepatitis B, which has successfully completed Phase I clinical trials. Altimmune also develops NasoShield, an intranasal anthrax vaccine, and NasoVAX, a recombinant intranasal vaccine. Additionally, the company is advancing AdCOVID, a single-dose intranasal vaccine for COVID-19. In the preclinical stage, Altimmune is working on ALT-801, a peptide-based dual GLP-1/glucagon receptor agonist for non-alcoholic steatohepatitis, as well as ALT-702, a tumor immunostimulant aimed at cancer treatment. The company employs proprietary technology for non-invasive intranasal delivery of its products and collaborates with institutions such as the University of Alabama at Birmingham to further its research initiatives.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

Velico Medical, Inc. is a pre-clinical medical technology company based in Beverly, Massachusetts, focused on developing and commercializing innovative products for the preparation and storage of platelets and plasma. The company's key offerings include FrontlineODP (On Demand Plasma), which allows blood centers to produce plasma in a dried powder form, eliminating the need for traditional freezing methods. Additionally, Velico Medical provides the FrontlinePPS (Platelet Protection System), designed to reduce the deterioration of platelets during storage. By creating advanced solutions for blood product management, Velico Medical aims to enhance transfusion practices and ultimately contribute to reducing preventable deaths from bleeding. The company was previously known as ZymeQuest, Inc. and has been in operation since 1991.

Sanofi Pasteur SA is a prominent global developer and manufacturer of vaccines, headquartered in Lyon, France. The company specializes in producing vaccines for a wide range of bacterial and viral diseases, including pertussis, diphtheria, typhoid fever, poliomyelitis, influenza, and mumps. Established in 1990, Sanofi Pasteur has a significant international presence with production facilities located in France, the United States, Canada, China, Thailand, and Argentina. Formerly known as Aventis Pasteur S.A., the company adopted its current name in 2004 and operates as a subsidiary of Sanofi-Aventis, contributing to public health through its extensive vaccine portfolio.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Soligenix, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases and public health solutions. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma that has completed Phase 3 clinical trials, and SGX942, aimed at treating oral mucositis in head and neck cancer, currently in Phase 3 trials. Additionally, it is developing an oral formulation of beclomethasone dipropionate for severe gastrointestinal disorders in early clinical trials. The Public Health Solutions segment focuses on biodefense, including the development of RiVax, a vaccine candidate against ricin toxin, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections that is in pre-clinical development. The company also works on technologies like ThermoVax, aimed at stabilizing vaccines. Soligenix was founded in 1987 and is based in Princeton, New Jersey.

Terumo is a prominent healthcare company based in Tokyo, specializing in the manufacture and distribution of medical products, equipment, and pharmaceuticals. With a legacy of nearly 100 years in the industry, Terumo employs over 25,000 associates globally, delivering innovative medical solutions across more than 160 countries. The company's diverse portfolio encompasses three main business segments: blood management, cardiac and vascular, and general hospital products. The cardiac and vascular division, which generates the largest share of revenue, focuses on interventional therapies, cardiovascular surgical systems, and neurovascular products. Additionally, the general hospital segment includes offerings related to diabetes management, consumer healthcare, and various medical technologies. Committed to "Contributing to Society through Healthcare," Terumo continues to enhance the quality of patient care and support healthcare professionals worldwide.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company based in New York, specializing in health security and infectious disease markets. Established in 1995, the company develops antiviral drugs targeting lethal pathogens, including variola virus, which causes smallpox. Its primary product, TPOXX, is an orally administered antiviral treatment specifically designed for human smallpox disease. SIGA is dedicated to creating modern biodefense countermeasures against high-priority viral threats, aiming to prevent and treat diseases such as Ebola, dengue, and Lassa fever. The company primarily generates revenue from the United States market.